| 3.71 0.01 (0.27%) | 08-18 09:50 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.89 | 1-year : | 5.71 |
| Resists | First : | 4.19 | Second : | 4.89 |
| Pivot price | 3.61  |
|||
| Supports | First : | 3.53 | Second : | 3.13 |
| MAs | MA(5) : | 3.82 |
MA(20) : | 3.56 |
| MA(100) : | 3.54 |
MA(250) : | 3.77  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.2 |
D(3) : | 68 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 5.01 | Low : | 2.72 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CCEL ] has closed below upper band by 36.3%. Bollinger Bands are 19.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4 - 4.02 | 4.02 - 4.03 |
| Low: | 3.63 - 3.65 | 3.65 - 3.67 |
| Close: | 3.66 - 3.7 | 3.7 - 3.73 |
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Fri, 07 Aug 2026
Cryo-Cell International (CCEL) moves 600,191 shares to new 2026 trust - Stock Titan
Wed, 15 Jul 2026
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results - Business Wire
Wed, 15 Jul 2026
CRYO CELL INTERNATIONAL INC Q2 2026: Revenue $7.78M (Q2), $15.46M (6 months) — 10-Q Summary - TradingView
Tue, 07 Jul 2026
Camac Fund holds 6.8% Cryo-Cell (CCEL) stake and may engage board - Stock Titan
Fri, 08 May 2026
Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|